Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of CRISPR/Cas9-based gene editing therapies. The company operates within the biotechnology and life sciences industries, with a strategic emphasis on treating severe and life-threatening diseases through in vivo and ex vivo genome editing. Its core value proposition is the ability to make precise, durable genetic edits directly in patients or in engineered cells, potentially enabling one-time, curative treatments.
Founded in 2014, Intellia was established by pioneers in CRISPR technology, including Nessan Bermingham and Jennifer Doudna, shortly after the foundational CRISPR-Cas9 discoveries. The company went public in 2016 and has since evolved from a platform-focused research organization into a clinical-stage company with multiple human proof-of-concept programs. Intellia’s strategy centers on leveraging its proprietary gene-editing platform and lipid nanoparticle delivery technology to address genetic diseases with high unmet medical need.
Business Operations
Intellia’s operations are organized around two primary therapeutic approaches: in vivo genome editing and ex vivo genome editing. In vivo programs involve delivering CRISPR components directly into the body to edit disease-causing genes within target tissues, primarily the liver. Key revenue drivers to date have consisted of collaboration revenue, research funding, and milestone payments rather than product sales, as the company does not yet have commercialized therapies.
The company controls proprietary CRISPR/Cas9 constructs, guide RNA designs, and lipid nanoparticle delivery systems that enable targeted gene editing. Intellia maintains strategic collaborations, most notably with Regeneron Pharmaceuticals, which focuses on the discovery and development of in vivo gene-editing therapies for certain targets. Intellia also operates through wholly owned subsidiaries, including Intellia Therapeutics Ltd., which supports international research and development activities.
Strategic Position & Investments
Intellia’s strategic direction is centered on advancing first-in-class and best-in-class genome-editing medicines, with near-term focus on late-stage clinical development of lead candidates such as NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. These programs have positioned the company as a leader in systemic in vivo CRISPR-based therapeutics, a field with limited direct competition at similar stages of development.
The company has made significant investments in manufacturing capabilities, delivery technologies, and next-generation gene-editing tools to expand beyond liver-targeted diseases. While Intellia previously maintained a broad strategic alliance with Novartis, that collaboration concluded, and the company has since focused its capital allocation on internal pipeline development and selective partnerships. Data on additional undisclosed investments or early-stage portfolio assets is inconclusive based on available public sources.
Geographic Footprint
Intellia is headquartered in Cambridge, Massachusetts, a major global hub for biotechnology research and development. Its primary operations, including executive leadership, research laboratories, and clinical development activities, are based in the United States.
Internationally, the company maintains a presence in Europe, primarily through its UK subsidiary, supporting research, regulatory, and clinical trial activities. While Intellia does not operate commercial facilities across multiple continents, its clinical trials, collaborations, and intellectual property footprint provide it with operational influence in North America and Europe, with potential future expansion tied to regulatory approvals and commercialization.
Leadership & Governance
Intellia is led by an executive team with deep experience in biotechnology, pharmaceuticals, and genomic medicine. The leadership emphasizes a science-driven culture, disciplined clinical execution, and long-term value creation through transformative therapies. Governance is overseen by a board that includes industry veterans and scientific leaders in gene editing.
Key executives include:
- John Leonard – President and Chief Executive Officer
- Nessan Bermingham – Founder and Chief Scientific Officer
- Michelle Robertson – Chief Financial Officer
- Regina Whitman – Chief Operating Officer
- Lynn Connolly – Chief Legal and Administrative Officer